Compare Garmin Ltd. (GRMN) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

Garmin (GRMN) trades at $310.89, up 2.96% today and near its all-time high, with a bullish technical trend supported by moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.81 versus $2.30 expected, and raised full-year guidance. Revenue growth is robust, driven by the fitness segment, with 2025 revenue at $7.25 billion and net income margin of 24.47%.

Outlook is positive due to sustained demand for wearables and upward revisions, but risks include rich valuations (P/E of 32.08) and potential growth deceleration. Analyst consensus is cautious with 74% hold ratings, though the price target of $318.67 suggests modest upside. Investors should weigh strong fundamentals against high expectations.

Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.

Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.